Skip to content

Author

April W. Armstrong

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Icotrokinra, a Targeted Oral Peptide, in Participants With Moderate-to-Severe Plaque Psoriasis and Self-Reported Psoriatic Arthritis: Results From a Pooled Analysis of the Phase 3 ICONIC-LEAD, ICONIC-ADVANCE 1, and ICONIC-ADVANCE 2 Trials

Background Icotrokinra, a targeted oral peptide that precisely blocks the interleukin-23 receptor, is approved to treat adult and pediatric (≥12 years, ≥40 kg) patients with moderate-to-severe plaque psoriasis (PsO). Objective Assess psoriatic arthritis (PsA)–specific outcomes through Week (W) 16 in a subgroup of phase...

I. McInnes, L. Stein-Gold, R. Bissonnette et al. · 0 citations
Oct 2026

52-Week Safety and Disease Control With Ruxolitinib Cream in Children Aged 2 to 11 Years With Atopic Dermatitis: Results From the Phase 3 TRuE-AD3 Study.

BACKGROUND Ruxolitinib (selective Janus kinase [JAK]1/JAK2 inhibitor) cream demonstrated efficacy and safety vs vehicle during 8 weeks of continuous use in a phase 3 study of children with atopic dermatitis (AD). OBJECTIVE To evaluate long-term safety (LTS) and disease control with as-needed ruxolitinib cream use in...

A. Paller, L. Stein Gold, E. Simpson et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.